New, easy to use, low-cost technologies based on DNA origami biosensing to achieve distributed screening for AMR and improved antibiotic prescribing

基于 DNA 折纸生物传感的易于使用、低成本的新型技术，可实现 AMR 的分布式筛查并改进抗生素处方

• 批准号: MR/Y034481/1
• 负责人: Damion Corrigan
• 金额: $ 45.76万
• 依托单位: University of Strathclyde
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FY034481%2F1
• 关键词: New; easy; use; low; cost

Biosensing technologies have great potential to help realise an age where healthcare can be delivered more efficiently due to an accelerated, simplified and less expensive diagnostic pathway. Antimicrobial resistance (AMR) is one of the most significant societal challenges we face and because of its nature requires a coordinated global response. Without action, by 2050, AMR could lead to 10 million deaths globally each year making it more dangerous that cancer and heart disease combined. AMR is a multifaceted problem with many paths to improving the situation. Two key aspects are diagnosis and targeted prescribing of drugs. This project will assist with these two challenges by developing cutting-edge diagnostic technologies which are highly sensitive, highly accurate but crucially low cost and highly manufacturable because the designed sensors will rely on the use of simple, easy to source and highly manufacturable components such as synthetic DNA, low-cost test strips and quartz-based materials. By exploiting developments in an emerging area of nanotechnology (DNA origami) the project will utilise precisely designed DNA shapes and structures attached to sensor surfaces to sense for the presence of bacteria and key drug resistance genes first in simulated and finally in clinical samples with high analytical sensitivity and high precision. The findings of the project will be used to develop the next generation of medical devices which will operate by the high sensitivity and high accuracy sensing mechanisms developed in this project.

生物传感技术具有巨大的潜力，可以通过加速、简化和更便宜的诊断途径来帮助实现更有效地提供医疗保健的时代。抗菌素耐药性 (AMR) 是我们面临的最重大的社会挑战之一，由于其性质，需要全球采取协调一致的应对措施。如果不采取行动，到 2050 年，抗菌素耐药性每年可能导致全球 1000 万人死亡，其危险性将超过癌症和心脏病的总和。抗菌素耐药性是一个多方面的问题，有多种改善这种情况的途径。两个关键方面是诊断和有针对性的药物处方。该项目将通过开发尖端诊断技术来应对这两个挑战，这些技术具有高灵敏度、高精度，但成本极其低廉且可制造性高，因为设计的传感器将依赖于使用简单、易于采购且可制造性高的组件，例如合成 DNA、低成本测试条和石英材料。通过利用纳米技术（DNA折纸）新兴领域的发展，该项目将利用附着在传感器表面的精确设计的DNA形状和结构，首先在模拟中检测细菌和关键耐药基因的存在，最后在具有高分析能力的临床样本中检测细菌和关键耐药基因的存在。灵敏度高、精度高。该项目的研究结果将用于开发下一代医疗设备，该设备将通过该项目开发的高灵敏度和高精度传感机制进行操作。